Anger Thomas, Pohle Falk K, Kandler Lukas, Barthel Thomas, Ensminger Stephan M, Fischlein Theodor, Weyand Michael, Stumpf Christian, Daniel Werner G, Garlichs Christoph D
Department of Cardiology, Friedrich-Alexander University Erlangen, Germany.
Exp Mol Pathol. 2007 Dec;83(3):435-42. doi: 10.1016/j.yexmp.2007.02.008. Epub 2007 Mar 24.
Sclerotic calcification of the aortic valve is a common disease in advanced age. Its pathophysiology is unclear. However, pathobiological similarities to atherosclerosis have been shown in several studies. The current study assesses gene profiling of severe calcified stenotic human aortic valves identifying transforming growth factor (TGF)-beta, Eotaxin3, vascular adhesion protein-1 (VAP-1) and monokine induced by interferon-gamma (MIG) as potential atherosclerotic target genes in severe calcified and stenotic aortic valves, and analyzes the effects of statins on their expression as part of an anti-inflammatory treatment strategy. We collected human severe calcified and stenotic aortic valves with (CSAV+) or without (CSAV-) statin pre-treatment prior to valve replacement and investigated gene profiling by using micro-array technique and real-time PCR for the TGF-beta, Eotaxin3, VAP-1 and MIG expression. In comparison to atherosclerotic plaques of carotid arteries, immunohistochemical staining was investigated. Results were contrasted to human normal non-calcified aortic valves as controls (C). As compared to C, TGF-beta, Eotaxin3, MIG or VAP-1 was significantly upregulated in CSAV-. In CSAV+ no significant change in gene expression was found for Eotaxin3 and MIG. In contrast, VAP-1 and TGF-beta were still upregulated. Corresponding gene expression was confirmed on atherosclerotic plaque formations of carotid arteries. Monocyte/Macrophage infiltration (presence of CD68) on aortic valves (CSAV+, CSAV-, or C) confirmed inflammatory nature of the disease. Our data support further evidence for atherosclerotic inflammation as a trigger for sclerosis in end-stage calcified stenotic aortic valves by showing upregulation of gene expression for TGF-beta, VAP-1, MIG and Eotaxin3, which is only partially inhibited by previous statin therapy. Potent benefits of statin treatment on early stages of valve disease are still propagated.
主动脉瓣硬化性钙化是一种常见于老年的疾病。其病理生理学尚不清楚。然而,多项研究已表明其与动脉粥样硬化在病理生物学上存在相似性。本研究评估重度钙化狭窄的人类主动脉瓣的基因谱,确定转化生长因子(TGF)-β、嗜酸性粒细胞趋化因子3、血管黏附蛋白-1(VAP-1)和干扰素-γ诱导的单核因子(MIG)为重度钙化狭窄主动脉瓣中潜在的动脉粥样硬化靶基因,并分析他汀类药物对其表达的影响,作为抗炎治疗策略的一部分。我们在瓣膜置换前收集了接受(CSAV+)或未接受(CSAV-)他汀类药物预处理的人类重度钙化狭窄主动脉瓣,并通过微阵列技术和实时PCR研究TGF-β、嗜酸性粒细胞趋化因子3、VAP-1和MIG表达的基因谱分析。与颈动脉粥样硬化斑块相比,进行了免疫组织化学染色。结果与作为对照(C)的人类正常非钙化主动脉瓣进行对比。与C相比,CSAV-中TGF-β、嗜酸性粒细胞趋化因子3、MIG或VAP-1显著上调。在CSAV+中,嗜酸性粒细胞趋化因子3和MIG的基因表达未发现显著变化。相反,VAP-1和TGF-β仍上调。在颈动脉粥样硬化斑块形成中证实了相应的基因表达。主动脉瓣(CSAV+、CSAV-或C)上的单核细胞/巨噬细胞浸润(CD68的存在)证实了该疾病的炎症性质。我们的数据通过显示TGF-β、VAP-1、MIG和嗜酸性粒细胞趋化因子3基因表达上调,为动脉粥样硬化炎症作为终末期钙化狭窄主动脉瓣硬化的触发因素提供了进一步证据,而先前他汀类药物治疗仅部分抑制了这种上调。他汀类药物治疗对瓣膜疾病早期阶段的显著益处仍在传播中。